Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 647.19

+0.5%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Torben Noerup Nielsen who wrote (362)	1/3/2000 8:43:00 PM
From: Miljenko Zuanic	Read Replies (1) of 3557

Torben, It isn't my does, it is from REGN PR news (however, bit of the hype from my side doesn't hurt): Message 11136105 .... The Company summarized preliminary, interim results of the Phase I safety study of AXOKINE in a small number of mildly to moderately obese healthy volunteers. In that study, the nine patients who received daily administration of low doses of AXOKINE for 14 days lost weight and had decreased food intake. .... They lost average 4-5 kg/therapy (two weeks). Dose were 0.5, 1.0, and 2.0 mc-gr/kg, 3 pts per arm, 3 in placebo arm. The doses which didn't reactivate HSV during 14 days therapy. It doesn't mean that it will not in longer duration therapy. Regardless all this, you don't need Axokine for reasonable return with REGN investment. Axokine is currently <zero in REGN market capitalization, imo. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next